Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR8 | P51685 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8324162 | 0.78 | CCR1 (0.43) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL29468208 | 0.77 | AHR (0.47) | AHRCDC7CDK2KDM4ECYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28471192 | 0.77 | CCR1 (0.42) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL28166205 | 0.77 | KDM4E (0.42) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL19233651 | 0.77 | CDC7 (0.46) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL31298631 | 0.77 | KDM4E (0.42) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL10366831 | 0.76 | CCNB2 (0.46) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL12724778 | 0.74 | KDM4E (0.57) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL10218716 | 0.74 | KDM4E (0.40) | AHRCDC7CDK2KDM4ECYP3A4 | |
| SCHEMBL19841330 | 0.74 | RORC (0.41) | AHRCDC7CDK2KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082069-A1 | COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN | 中国海洋大学 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841843-A | Compound combined with CRBN protein and degradation agent of CRBN protein | 中国海洋大学 | 2025-04-18 | — | — | CN | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| US-10544149-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-01-28 | — | — | US | disclosed |
| EP-3555094-A1 | BICYCLIC OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-12 | — | — | US | disclosed |
| WO-2018109198-A1 | BICYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| US-9884867-B2 | Bicyclic alkyne derivatives and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-06 | — | — | US | disclosed |
| US-20160229860-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-11 | — | — | US | disclosed |
| EP-3052501-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050505-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-04-09 | — | — | WO | disclosed |
| CN-102584830-A | Dihydroindene amide compounds, and medicinal composition and application thereof | BEIJING SAILINTAI PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229860-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | MAPKAPK2, CAMKK2, MKNK2 | AHR 818/4885CDC7 937/4885CDK2 219/4885 |
| US-10544149-B2 | Bicyclic alkyne derivatives and uses thereof | MAPKAPK2, MAP4K2, MKNK2 | AHR 766/4885CDC7 925/4885CDK2 217/4885 |
| US-20180194771-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | MAPKAPK2, CAMKK2, MKNK2 | AHR 818/4885CDC7 937/4885CDK2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.